Blueprint Investment Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-4,590
Closed -$3.54M 157
2024
Q4
$3.54M Sell
4,590
-327
-7% -$271K 0.56% 38
2024
Q3
$4.36M Buy
4,917
+225
+5% +$202K 0.79% 25
2024
Q2
$4.25M Buy
4,692
+1,628
+53% +$1.3M 0.92% 23
2024
Q1
$2.38M Sell
3,064
-141
-4% -$100K 0.47% 33
2023
Q4
$1.87M Buy
3,205
+764
+31% +$446K 0.51% 40
2023
Q3
$1.31M Buy
2,441
+403
+20% +$208K 0.42% 41
2023
Q2
$956K Sell
2,038
-178
-8% -$74.6K 0.34% 49
2023
Q1
$761K Sell
2,216
-4,233
-66% -$1.43M 0.17% 76
2022
Q4
$2.36M Buy
6,449
+457
+8% +$162K 0.5% 46
2022
Q3
$1.94M Buy
5,992
+2,512
+72% +$796K 0.53% 38
2022
Q2
$1.13M Buy
3,480
+1,847
+113% +$554K 0.3% 56
2022
Q1
$468K Sell
1,633
-241
-13% -$62K 0.12% 100
2021
Q4
$518K Buy
1,874
+723
+63% +$183K 0.13% 122
2021
Q3
$266K Buy
+1,151
New +$284K 0.13% 107

Other funds holding LLY

Blueprint Investment Partners's LLY Position: Q1 2025 in Review

Blueprint Investment Partners sold out of Eli Lilly (LLY) in Q1 2025, closing a stake of 4,590 shares — an estimated $3.54M sold.

Blueprint Investment Partners first reported a position in LLY in Q3 2021 and held it in 14 quarters. The position peaked at $4.36M in Q3 2024. 3,919 funds tracked by Wall St. Rank hold LLY as of Q1 2025.

  • Blueprint Investment Partners reported no remaining Eli Lilly position as of Q1 2025 after selling out during the quarter.
  • Blueprint Investment Partners sold 4,590 Eli Lilly shares in Q1 2025, an estimated $3.54M.
  • Blueprint Investment Partners first reported a position in Eli Lilly in Q3 2021 and held it in 14 quarters.
  • Blueprint Investment Partners's Eli Lilly position peaked at $4.36M in Q3 2024.
  • 3,919 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.

Based on Blueprint Investment Partners's 13F filing for Q1 2025, filed 12 May 2025.